Canon Medical’s Alphenix Evolve Angiography System Launched in Europe

August 4, 2023—Canon Medical announced the European market introduction of the Alphenix Evolve edition, an angiography system for percutaneous coronary intervention (PCI) and structural heart disease procedures. The Alphenix Evolve edition is designed to enhance imaging while enabling reduced time and radiation dose during routine and complex procedures.

The company conducted an online launch via LinkedIn during CVIT 2023, the 31st annual meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics held August 4-6 in Fukuoka, Japan.

Packaged under Canon’s αEvolve technology umbrella of artificial intelligence solutions, the system offers a range of features for the interventional cardiology suite that provides real-time assistance to support diagnostic and therapeutic decisions without interrupting the workflow, stated the company.

According to the company, the Alphenix Evolve edition includes αEvolve’s noise reduction and multifrequency processing that enable clear fluoroscopic imaging, which can deliver a two-times–higher contrast-to-noise ratio compared to conventional image processing.

A dynamic device stabilizer detects balloon markers in real-time, magnifying and stabilizing an image on a separate screen to assist in visualization and assessment during complex PCI procedures.

For structural heart procedures such as left atrial appendage closure, the system’s Echo Fusion identifies the echocardiography probe and fuses the fluoroscopic and echo image without additional operator input.

In addition, the Alphenix Evolve edition includes a 12- X 12-inch flat panel detector that provides procedural flexibility and a dose tracking system for real-time information on radiation dose, noted the company.